Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5162-5167

  Baker, Amanda ^a   Payne, Claire M ^b   Briehl, Margaret M ^c   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; PROTEIN BCL 2; SPHINGOSINE DERIVATIVE; STAUROSPORINE; THAPSIGARGIN; THIOREDOXIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REGULATORY MECHANISM; SCID MOUSE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; DEXAMETHASONE; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; MICE; MICE, SCID; NEOPLASM PROTEINS; SPHINGOSINE; STAUROSPORINE; THAPSIGARGIN; THIOREDOXIN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030695172     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem., 264: 13963-13966, 1989.
2. Luthman, M., and Holmgren, A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry, 21: 6628-6633, 1982.
3. Gasdaska, P. Y., Oblong, J. E., Cotgreave, I. A., and Powis, G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta, 1218: 292-296, 1994.
4. Laurent, T. C., Moore, E. C., and Reichard, P. Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem., 239: 3436-3444, 1964.
5. Matthews, J. R., Wakasugi, N., Virelizier, J-L., Yodoi, J., and Hay, R. T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res., 20: 3821-3830, 1992.
6. Cromlish, J. A., and Roeder, R. G. Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J. Biol. Chem., 264: 18100-18109, 1989.
7. Bannister, A. J., Cook, A., and Kouzarides, T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene, 6: 1243-1250, 1991.
8. Grippo, J. F., Tienrungroj, W., Dahmer, M. K., Housley, P. R., and Pratt, W. B. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J. Biol. Chem., 258: 13658-13664, 1983.
9. Abate, C., Patel, L., Rauscher, F. J., III, and Curran, T. Redox regulation of fos and jun DNA-binding activity in vitro. Science (Washington DC), 249: 1157-1161, 1990.
10. Powis, G., Oblong, J. E., Gasdaska, P. Y., Berggren, M., Hill, S., and Kirkpatrick, D. L. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol. Res., 6: 539-544, 1994.
11. Oblong, J. E., Berggren, M., Gasdaska, P. Y., and Powis, G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem., 269: 11714-11720, 1994.
12. Gasdaska, J. R., Berggren, M., and Powis, G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ., 6: 1643-1650, 1995.
13. Berggren, M., Gallegos, A., Gasdaska, J. R., Gasdaska, P. Y., Warneke, J., and Powis, G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res., 16: 3459-3466, 1996.
14. Fujii, S., Nanbu, Y., Nonogaki, H., Konishi, I., Mori, T., Masutani, H., and Yodoi, J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer (Phila.), 68: 1583-1591, 1991.
15. Kawahara, N., Tanaka, T., Yokomizo. A., Nanri. H., Ono, M., Wada, M., Kohno, K., Takenaka, K., Sugimachi, K., and Kuwano, M. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res., 56: 5330-5333, 1996.
16. Gallegos, A., Gasdaska, J. R., Taylor, C. W., Paine-Murrieta, G. D., Goodman, D., Gasdaska, P. Y., Berggren, M., Briehl, M. M., and Powis, G. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res., 56: 5765-5770, 1996.
17. Briehl, M. M., Cotgreave, I. A., and Powis, G. Downregulation of the antioxidant defense during glucocorticoid-mediated apoptosis. Cell Death Differ., 2: 41-46, 1995.
18. Harris, A. W., Bankhurst, A. D., Mason, S., and Warner, N. L. Differentiated functions expressed by cultured mouse lymphoma cells II. θ antigen, surface immunoglobulin and a receptor for antibody on cells of a thymoma cell line. J. Immunol., 110: 431-438, 1973.
19. 2+ fluxes. Proc. Natl. Acad. Sci. USA, 91: 6569-6573, 1994.
20. Rundlett, S. E., Gordon, D. A., and Miesfeld, R. L. Characterization of a panel of rat ventral prostate epithelial cell lines immortalized in the presence or absence of androgens. Exp. Cell Res., 203: 214-221, 1992.
21. Leist, M., Gartner, F., Bohlinger, I., Tiegs, G., and Wendel, A. Application of the cell death detection ELISA for the detection of tumor necrosis factor-induced DNA fragmentation in murine models of inflammatory organ failure. Biochemica, 11: 20-22, 1994.
22. Philpott, N. H., Turner, A. J. C., Scopes, J., Westby, M., Marsh, J. C. W., Gordon-Smith, E. C., Daigleish, A. G., and Gibson, F. M. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood, 6: 2244-2251, 1996.
23. Kondo, Y., Woo, E., Michalska, A. E., Choo, A. C., and Lazo, J. S. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res., 55: 2021-2023, 1995.
24. Pushkareva, M., Obeid, L. M., and Hannun, Y. A. Ceramide: an endogenous regulator of apoptosis and growth suppression. Immunol. Today, 16: 294-297, 1995.
25. Onishi, Y., Azuma, Y., Sato, Y., Mizuno, Y., Tadakuma, T., and Kizaki, H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim. Biophys. Acta, 1175: 147-154, 1993.
26. Matsuda. M., Masutani, H., Nakamura, H., Miyajima, S., Yamauchi, A., Yonehara, S., Uchida, A., Irimajiri, K., Horiuchi, A., and Yodoi, J. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cylotoxicity on U937 cells. J. Immunol., 147: 3837-3841, 1991.
27. Baker, A. F., Briehl, M. M., Dorr, R., and Powis, G. Decreased antioxidant defense and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 selectively prevents the loss of catalase activity. Cell Death Differ., 3: 207-213, 1996.
28. Shimizu, S., Eguchi, Y., Kamiike, W., Matsuda, H., and Tsujimoto, Y. Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene, 12: 2251-2257, 1996.
29. Hockenberry, D. M., Oltvai, Z. N., Yin, X., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251, 1993.
30. Jacobsen, M. D., Burne, J. F., and Raff, M. C. Programmed cell death and bcl-2 protection in the absence of a nucleus. EMBO J., 13: 1899-1910, 1994.
31. Jacobson, M. D., and Raff, M. C. Programmed cell death and Bcl-2 protection in very low oxygen. Nature (Lond.), 374: 814-816, 1995.
32. Wolfe, J. T., Ross, D., and Cohen, G. M. A role for metals and free radicals in the induction of apoptosis in thymocytes. FEBS Lett., 352: 58-62, 1994.
33. Salgo, M. G., and Pryor, W. A. Trolox inhibits peroxynitrite-mediated oxidative stress and apoptosis in rat thymyocytes. Arch. Biochem. Biophys., 333: 482-488, 1996.
34. Reed, J. C., Miyashita, T., Takayama, S., Wang, H., Sato, T., Krajewski, S., Aimé-Sempé, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
35. Maeyama, Y. Enhanced expression of bcl-2 inhibits apoptosis in cultured human keratinocytes. Kurume Med. J., 42: 291-297, 1995.
36. McDonnell, T. J., and Korsmeyer, S. J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature (Lond.), 349: 254-256, 1991.
37. Kuperus, M., and Kirkpatrick, D. L. Interaction of redox active disulfides with the autocrine growth factor, human thioredoxin. Proc. Am. Assoc. Cancer Res., 36: 426, 1995.
38. Powis, G., Kirkpatrick, D. L., Angulo, M., Gasdaska, J. R., Powell, M. B., Salmon, S. E., and Montfort, W. R. Thioredoxin redox signalling: a novel target for anticancer drug development. Anticancer Drugs, 7 (Suppl. 3): 121-126, 1996.